CoChat

GLP1 and cancer: friend or foe?

Open access
Vangoitsenhoven, Roman, Mathieu, Chantal, Van der Schueren, Bart · 2012 · Endocrine-Related Cancer
Cited by 73

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

The new incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon like peptide 1 (GLP1) receptor agonists are widely used for the treatment of type 2 diabetes because of their glucose-lowering capacity with low risk of hypoglycemia. As they are weight neutral or induce weight loss in this mostly overweight population, they are popular among clinicians and patients alike. Nonetheless, concerns have been raised about GLP1's trophic effects. While increased β cell mass observed in rodents sounds appealing for treatment of diabetes, there was also an increased incidence of medullary thyroid cancer (MTC) in some species. We reviewed literature available in the Medline database until March 2012. Safety signals have emerged for MTC and pancreatic carcinoma from adverse event databases in the United States and Europe. Considering the relatively short duration of these studies, it is more likely that premalignant lesions are stimulated in presence of GLP1, rather than new neoplasms induced. Moreover, interpreting results of animal studies is difficult because of species-specific differences in presence and density of GLP1 receptors. Furthermore, data are emerging suggesting beneficial effects of GLP1 on colon and breast cancer. In conclusion, presently, the benefits of using DPP4 inhibitors or GLP1 receptor agonists for treatment of type 2 diabetes outweigh the risks. Nonetheless, their safety profile should be monitored and their indications should be widened cautiously. At present they remain contra-indicated in patients with a personal or family history of MTC or multiple endocrine neoplasia type 2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/erc-12-0111

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 49

  1. 2004, BEST PRACTICE RESEARCH CLINICAL ENDOCRINOLOGY METABOLISM, 18, 531, 10.1016/j.beem.2004.08.001 · DOI
  2. 2009, JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 3, 245, 10.1016/j.jash.2009.04.001 · DOI
  3. Bayliss, 1902, The Journal of Physiology, 28, 325, 10.1113/jphysiol.1902.sp000920 · DOI · Paper page
  4. Blomgren, 2002, Diabetes Care, 25, 298, 10.2337/diacare.25.2.298 · DOI · Paper page
  5. 2004, Endocrinology, 145, 2653, 10.1210/en.2004-0015 · DOI · Paper page
  6. Bullock, 1996, Endocrinology, 137, 2968, 10.1210/en.137.7.2968 · doi:10.1210/en.137.7.2968 · Paper page
  7. Butler, 2010, 53, 21, 10.1007/s00125-009-1556-8 · DOI · Paper page
  8. Cure, 2008, New England Journal of Medicine, 358, 1969, 10.1056/NEJMc0707137 · DOI · Paper page
  9. 2011, DIABETES OBESITY METABOLISM, 13, 559, 10.1111/j.1463-1326.2011.01376.x · DOI · Paper page
  10. Drucker, 2011, Lancet, 377, 977, 10.1016/S0140-6736(10)62299-4 · DOI
  11. Drucker, 1986, Journal of Biological Chemistry, 261, 9637, 10.1016/S0021-9258(18)67561-1 · DOI · Paper page
  12. Drucker, 1996, PNAS, 93, 7911, 10.1073/pnas.93.15.7911 · DOI · Paper page
  13. Fehmann, 1992, Endocrinology, 130, 159, 10.1210/en.130.1.159 · DOI · Paper page
  14. Fineman, 2003, Diabetes Care, 26, 2370, 10.2337/diacare.26.8.2370 · DOI · Paper page
  15. Gallagher, 2011, Annals of the New York Academy of Sciences, 1243, 54, 10.1111/j.1749-6632.2011.06285.x · DOI · Paper page
  16. 2010, Diabetes Care, 33, 2349, 10.2337/dc10-0482 · DOI · Paper page
  17. Ghatei, 2001, Digestive diseases and sciences, 46, 1255, 10.1023/A:1010615429639 · DOI
  18. 1984, 27, 599, 10.1007/BF00276976 · DOI
  19. 2010, DIABETES OBESITY METABOLISM, 12, 766, 10.1111/j.1463-1326.2010.01231.x · DOI · Paper page
  20. Gromada, 1998, Diabetes, 47, 57, 10.2337/diab.47.1.57 · DOI · Paper page
  21. Hartmann, 2000, Endocrinology, 141, 4013, 10.1210/en.141.11.4013 · doi:10.1210/en.141.11.4013
  22. Havre, 2008, Frontiers in bioscience : a journal and virtual library, 13, 1634, 10.2741/2787 · DOI · Paper page
  23. Hjollund, 2011, 54, 2206, 10.1007/s00125-011-2168-7 · DOI
  24. 1997, American Journal of Physiology -- Legacy Content, 273, G920
  25. Jura, 2005, Cell research, 15, 72, 10.1038/sj.cr.7290269 · DOI
  26. Kieffer, 1995, Endocrinology, 136, 3585, 10.1210/en.136.8.3585 · DOI · Paper page
  27. Koehler, 2006, Diabetes, 55, 1369, 10.2337/diabetes. · doi:10.2337/diabetes · Paper page
  28. Koehler, 2008, Cancer Research, 68, 7897, 10.1158/0008-5472.CAN-08-0029 · DOI
  29. 2011, Endocrinology, 152, 3362, 10.1210/en.2011-1201 · DOI · Paper page
  30. Kreymann, 1987, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  31. Ligumsky, 2012, Breast cancer research and treatment, 132, 449, 10.1007/s10549-011-1585-0 · DOI
  32. Livolsi, 1979, American Journal of Clinical Pathology, 71, 595, 10.1093/ajcp/71.5.595 · DOI
  33. 2003, Journal of Biological Chemistry, 278, 52446, 10.1074/jbc.M307612200 · DOI · Paper page
  34. Masur, 2006, Regulatory peptides, 137, 147, 10.1016/j.regpep.2006.07.003 · DOI
  35. Matteucci, 2009, Current medicinal chemistry, 16, 2943, 10.2174/092986709788803114 · DOI · Paper page
  36. 2009, Diabetes, 58, 1604, 10.2337/db09-0058 · DOI · Paper page
  37. Munroe, 1999, PNAS, 96, 1569, 10.1073/pnas.96.4.1569 · DOI · Paper page
  38. NAUCK, 1989, Journal of Clinical Endocrinology & Metabolism, 69, 654, 10.1210/jcem-69-3-654 · DOI · Paper page
  39. 2010, New England Journal of Medicine, 362, 774, 10.1056/NEJMp1001578 · DOI · Paper page
  40. 2009, Gut, 58, 97, 10.1136/gut.2008.149179 · DOI · Paper page
  41. 2006, 107, 2134, 10.1002/cncr.22244 · DOI · Paper page
  42. 1983, 85, 1120
  43. Stoffers, 2000, Diabetes, 49, 741, 10.2337/diabetes.49.5.741 · DOI · Paper page
  44. Thulesen, 2004, Gut, 53, 1145, 10.1136/gut.2003.035212 · DOI · Paper page
  45. Tran, 1996, Cancer Epidemiology Biomarkers & Prevention, 5, 1013
  46. Tripathy, 2008, The Journal of the Association of Physicians of India, 56, 987
  47. Vilsboll, 2001, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 · DOI · Paper page
  48. Xia, 1995, Science, 270, 1326, 10.1126/science.270.5240.1326 · DOI · Paper page
  49. Xu, 1999, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B.
Venue
Endocrine-Related Cancer
Published
2012-06-12
Volume
19
Issue
5
Pages
F77-F88
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2136840982
Cited by
73
References
21
FWCI
3.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.